Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CCR1 | P32246 | 12/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464632 | 0.86 | KDM4E (0.47) | KDM4ERECQLALDH1A1CCR1GAA | |
| SCHEMBL1119950 | 0.84 | KDM4E (0.69) | KDM4ERECQLALDH1A1CCR1LMNA | |
| SCHEMBL3466044 | 0.82 | CCR1 (0.46) | KDM4ERECQLALDH1A1CCR1LMNA | |
| SCHEMBL111808 | 0.78 | ALDH1A1 (0.67) | KDM4ERECQLALDH1A1CCR1GAA | |
| SCHEMBL3464010 | 0.75 | ALDH1A1 (0.53) | KDM4ERECQLALDH1A1CCR1GAA | |
| SCHEMBL15679874 | 0.73 | ALDH1A1 (0.52) | KDM4ERECQLALDH1A1GAALMNA | |
| SCHEMBL14046017 | 0.73 | ALDH1A1 (0.51) | KDM4ERECQLALDH1A1CCR1GAA | |
| SCHEMBL13184187 | 0.73 | POLB (0.38) | KDM4ERECQLALDH1A1CCR1GAA | |
| SCHEMBL17229240 | 0.72 | ALDH1A1 (0.51) | KDM4ERECQLALDH1A1GAALMNA | |
| SCHEMBL15814354 | 0.72 | KDM4E (0.71) | KDM4ERECQLCCR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| CN-100542534-C | Substituted piperazines | CHEMOCENTRYX INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | KDM4E 3949/4885RECQL 4101/4885ALDH1A1 951/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | KDM4E 3949/4885RECQL 4101/4885ALDH1A1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.